Try Alerts Free   |   Login

DNMR Price Correlated With Financials For Danimer Scientific

Free historical financial statements for Danimer Scientific Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 7 quarters since 2021. Compare with DNMR stock chart to see long term trends.

DNMR Stock Compared to Quarterly

DNMR Income Statement

Revenue, Net:10448000
Revenue Per Share:0.103
Cost of Goods & Services Sold:14503000
Selling, General & Admin Expense:19413000
Research & Development Expense:7947000
Total Operating Expenses:105354000
Operating Income:-95112000
Income Taxes:-236000
Net Income:-94876000
Earnings Per Share, Basic:-0.94
Shares Outstanding, Basic Avg:101388673

DNMR Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:4584000
Change in Accounts Receiveable:-419000
Net Cash from Operations:-20189000
Net Cash from Operations Per Share:-0.1991
Net Cash from Financing Activities:22961000
Property, Plant & Equipment Purchases:24782000
Purchases of Businesses, Net of Cash:0
Net Cash from Investing Activities:-42819000
Net Change in Cash & Equivalents:-40047000

DNMR Balance Sheet

Cash and Cash Equivalents:100790000
Accounts Receivable, Net:17426000
Total Current Assets:162590000
Property, Plant & Equipment, Net:436875000
Total Assets:733375000
Accounts Payable:4324000
Current Portion of Long-Term Debt:1501000
Total Short-Term Liabilities:31569000
Total Liabilities:341654000

Major Holders (from 13F filings)

Investment Type
Value (x$1000)
increase or decrease
Blackrock Inc.
8,487,541 sh
-364,825 sh
Jefferies Group LLC
5,354,876 sh
3,554,876 sh
Vanguard Group Inc
4,969,731 sh
426,517 sh
Invesco Ltd.
2,835,360 sh
-1,224,212 sh
State Street Corp
1,939,088 sh
-22,130 sh
Greenlight Capital Inc
1,924,940 sh
1,103,940 sh
Geode Capital Management, LLC
1,552,350 sh
22,316 sh
Marshall Wace, Llp
1,425,358 sh
194,749 sh
Susquehanna International Group, Llp
Call options for 1,036,900 sh
1,036,900 sh
Capital Investment Advisors, LLC
833,403 sh
2,405 sh
Teramo Advisors, LLC
815,000 sh
100,000 sh
Northern Trust Corp
810,296 sh
-29,542 sh
Bnp Paribas Arbitrage, Sa
796,719 sh
796,719 sh
Royal Bank Of Canada
769,033 sh
3,564 sh
Charles Schwab Investment Management Inc
646,974 sh
32,516 sh
Newtyn Management, LLC
625,000 sh
Jefferies Group LLC
Call options for 595,000 sh
595,000 sh
Progeny 3, Inc.
521,757 sh
Graham Capital Management, L.P.
500,000 sh
Goldman Sachs Group Inc
490,835 sh
-2,479 sh
Note 1. Basis of Presentation Description of Business Danimer Scientific, Inc., together with its subsidiaries (“Company” , “Danimer”, “we”, “us”, or “our”), is a performance polymer company specializing in bioplastic replacements for traditional petroleum-based plastics. Our common stock is listed on the New York Stock Exchange under the symbol “DNMR”. The Company (formerly Live Oak Acquisition Corp. (“Live Oak”)), was originally incorporated in the State of Delaware on May 24, 2019 as a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses. Live Oak completed its initial public offering in May 2020. On December 29, 2020, Live Oak consummated a business combination (“Business Combination”) pursuant to an Agreement and Plan of Merger, dated as of October 3, 2020 (as amended by Amendment No. 1, dated as of October 8, 2020, and Amendment No. 2, dated as of December 11, 2020 (collectively “Merger Agreement”), by and among Live Oak, Green Merger Corp. (“Merger Sub.”), and Meredian Holdings Group, Inc. (“Legacy Danimer”). Immediately upon consummation of the Business Combination, Merger Sub. merged with and into Legacy Danimer, with Legacy Danimer surviving the merger as a wholly owned subsidiary of Live Oak. In connection with the Business Combination, Live Oak changed its name to Danimer Scientific, Inc. On August 11, 2021, we closed the acquisition of Novomer, Inc. (integrated into our business as “Danimer Catalytic Technologies”). Our consolidated results include those of Danimer Catalytic Technologies from the acquisition date forward. Refer to Note 2 for further discussion of the acquisition. Financial Statements The accompanying condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and consolidate all assets and liabilities of the Company and its wholly owned subsidiaries. GAAP requires us to make certain estimates and assumptions in recording assets, liabilities, sales and expenses as well as in the disclosure of contingent assets and liabilities. Actual results could differ from those estimates. All intercompany transactions and balances have been eliminated. Certain reclassifications have been made to previously reported amounts to conform to the current presentation. In preparing these condensed consolidated financial statements, we have considered and, where appropriate, included the effects of the COVID-19 pandemic on our operations. The pandemic continues to provide significant challenges to the U.S. and global economies. Since we do no t have any items of other comprehensive income or loss, there is no difference between net loss and comprehensive (loss) income for the three month periods ended March 31, 2022 or 2021, so a separate Statement of Comprehensive Income (Loss) that would otherwise be required is not presented. Recently Issued Accounting Pronouncements There have been no new accounting pronouncements not yet effective that we believe will have a significant effect, or potential significant effect, on our condensed consolidated financial statements.

Data imported from Danimer Scientific Inc. SEC filings. Check original filings before making any investment decision.